NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

January 4, 2028

Study Completion Date

March 4, 2030

Conditions

Advanced Biliary Tract CarcinomaAdvanced Colorectal CarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Lung AdenocarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Urothelial CarcinomaClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Lung AdenocarcinomaMetastatic Ovarian CarcinomaMetastatic Pancreatic CarcinomaMetastatic Urothelial CarcinomaRefractory Biliary Tract CarcinomaRefractory Colorectal CarcinomaRefractory Gastroesophageal Junction AdenocarcinomaRefractory Lung AdenocarcinomaRefractory Ovarian CarcinomaRefractory Pancreatic CarcinomaRefractory Urothelial CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Devimistat

Receive IV

DRUG

Fluorouracil

Receive IV

DRUG

Gemcitabine Hydrochloride

Receive IV

DRUG

Hydroxychloroquine

Receive PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER